Russian Heart Failure Journal 2012year administration of targeted drug delivery in treatment of heart failure

To access this material please log in or register

Register Authorize

administration of targeted drug delivery in treatment of heart failure

Uskov I. S., Grigorova Yu. N., Korolev D. V., Galagudza М. М.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: adenosine, ischemia, myocardium, silica nanoparticles, targeted delivery

DOI: 10.18087/rhfj.2012.2.1645

Relevance. MI is one of the main reasons of CHF development. After revascularization reperfusion of myocardium can invoke clinically significant enlargement of necrosis area. This situation requires pharmacological correction by cardioprotectors, yet they do have side effects. Use of directed delivery of medicinal products is possible to prevent the possibility of adverse effects. Objective. Consider the possibility of use of silica nanoparticles (SNP) as nanocarrier for the delivery of adenosine to ischemic myocardium. Materials and methods. Within the scope of study, the following experimental researches were planned: study of biodistribution of SNP suspension with immobilized fluorophores of fluorescein sodium (FLS-Na) and indocyanine green (ICG), in vitro and in vivo study of SNP biodegradation, influence of adsorbed adenosine infusion at SNP on BP in comparison with effects of free adenosine in the equivalent dose, assessment of infarction-limiting effect of free adenosine and adenosine adsorbed to SNP in the equivalent dose. Results. The finding of the study confirmed satisfactory biodegradation of the nanoparticle suspension in the in vitro experiment and in intravenous introduction of nanopartices in vivo. The study SNP biodistribution showed predominant accumulation in reticuloendothelial organs. It was demonstrated that adenosine adsorbed in the SNP surface has infarction-limiting effect.
  1. Deutsch E, Berger M, Kussmaul WG et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation. 1990;82 (6):2044–2051.
  2. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol. 1996;28 (5):1119–1126.
  3. Leesar MA, Stoddard MF, Xuan YT et al. Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. J Am Coll Cardiol. 2003;42 (3):437–445.
  4. Galagudza MM, Korolev DV, Sonin DL et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231–237.
  5. Wang AZ, Gu F, Zhang L et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther. 2008;8 (8):1063–1070.
  6. Takahama H, Minamino T, Asanuma H et al. Prolonged targeting of ische­mic / reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53 (8):709–717.
Uskov I. S., Grigorova Yu. N., Korolev D. V. et al. Administration of targeted drug delivery in treatment of heart failure. Russian Heart Failure Journal. 2012;13(2):93-100

To access this material please log in or register

Register Authorize
Ru En